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Abstract
Background: Muscle atrophy associated with various pathophysiological conditions represents a major health
problem, because of its contribution to the deterioration of patient status and its effect on mortality. Although the
involvement of pro-inflammatory cytokines in this process is well recognized, the role of sphingolipid metabolism
alterations induced by the cytokines has received little attention.
Results: We addressed this question both in vitro using differentiated myotubes treated with TNF-a, and in vivo in
a murine model of tumor-induced cachexia. Myotube atrophy induced by TNF-a was accompanied by a
substantial increase in cell ceramide levels, and could be mimicked by the addition of exogenous ceramides. It
could be prevented by the addition of ceramide-synthesis inhibitors that targeted either the de novo pathway
(myriocin), or the sphingomyelinases (GW4869 and 3-O-methylsphingomyelin). In the presence of TNF-a, ceramide-
synthesis inhibitors significantly increased protein synthesis and decreased proteolysis. In parallel, they lowered the
expression of both the Atrogin-1 and LC3b genes, involved in muscle protein degradation by proteasome and in
autophagic proteolysis, respectively, and increased the proportion of inactive, phosphorylated Foxo3 transcription
factor. Furthermore, these inhibitors increased the expression and/or phosphorylation levels of key factors
regulating protein metabolism, including phospholipase D, an activator of mammalian target of rapamycin (mTOR),
and the mTOR substrates S6K1 and Akt. In vivo, C26 carcinoma implantation induced a substantial increase in
muscle ceramide, together with drastic muscle atrophy. Treatment of the animals with myriocin reduced the
expression of the atrogenes Foxo3 and Atrogin-1, and partially protected muscle tissue from atrophy.
Conclusions: Ceramide accumulation induced by TNF-a or tumor development participates in the mechanism of
muscle-cell atrophy, and sphingolipid metabolism is a logical target for pharmacological or nutritional interventions
aiming at preserving muscle mass in pathological situations.
Background
A major complication arising from a variety of patholo-
gical states, including cancer, renal insufficiency, dia-
betes, and sepsis, is a loss of skeletal muscle tissue that
leads to reduced mobility and quality of life, lowered
response to treatments, and decreased life expectancy.
The causes of the muscle wasting that occurs during
chronic diseases are complex, but elevation of pro-
inflammatory cytokine levels, in particular TNF-a,i s
thought to play a prominent role [1]. TNF-a triggers
multiple cell responses, including ceramide formation,
through stimulation both of a de novo synthesis pathway
consisting of the condensation of palmitoyl-CoA with
serine, and of sphingomyelinase-mediated hydrolysis of
membrane sphingomyelin [2,3]. Ceramide is a bioactive
mediator involved in cell responses to stress [4]. It is
also the central compound of sphingolipid metabolism
that gives rise to more complex structural sphingolipids,
and to other bioactive mediators such as sphingosine or
sphingosine-1-phosphate (S1P) [5]. Whereas the involve-
ment of ceramide in the development of insulin resis-
tance in muscle and of type 2 diabetes has been largely
documented [6-8], very little is known about its role in
muscle-mass regulation, particularly in muscle atrophy.
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mide on a number of pathways able to affect this tissue,
such an involvement would be expected. Ceramide has
indeed been shown to inhibit myogenic differentiation
[9], amino acid transport, mammalian target of rapamy-
cin (mTOR) activity, and protein synthesis in myotubes
[10]. It can also enhance pathways involved in proteoly-
sis, such as the nuclear factor (NF)B pathway [11] and
autophagy [12,13].
We therefore hypothesized that the biosynthesis of
sphingolipid mediators, particularly ceramide, partici-
pates in the mechanisms leading to muscle loss asso-
ciated with pathological states. To test this assumption,
we used differentiated L6 and C2C12 myotubes treated
with TNF-a as in vitro models of muscle atrophy, and
an in vivo mouse model of tumor-induced cachexia [14].
Our results indicate that sphingolipids markedly influ-
ence the size and protein metabolism of differentiated
myotubes. In parallel, they affect the Akt/mTOR signal-
ing pathway, which is closely involved in the regulation
of protein synthesis and degradation [15,16], and phos-
pholipase D (PLD), an activator of this pathway [17,18].
The protective action of the inhibitor of de novo sphin-
golipid synthesis myriocin [19], which we observed both
in vitro and in vivo during tumor-induced cachexia, sug-
gests that preventing ceramide accumulation could
represent a promising strategy to preserve muscle mass
against the atrophy associated with a number of chronic
diseases.
Results
Both TNF-a and ceramide induce an in vitro atrophy of
cultured myotubes
In differentiated myotubes of the L6 cell line submitted
to 15 ng/ml recombinant TNF-a treatment for 3 days,
cell atrophy was present, as evidenced by a significant
decrease in cell surface, as already reported [20] (Figure
1a). Other parameters reflecting the functional status of
the differentiated muscle cells were also significantly
reduced by TNF-a treatment, such as the myosin heavy
chain (MHC) content, as evaluated by ELISA (Figure
1b), and the creatine kinase (CK) activity (Figure 1c).
Similarly, TNF-a treatment induced a decrease in cell
surface in myotubes derived from the C2C12 line (see
Additional file 1). We verified that in these conditions
TNF-a induced no change in cell viability (not shown).
The effects of TNF-a on cellular levels of sphingolipids
were assessed in L6 myotubes by tandem mass spectro-
metry (MS/MS). As expected, TNF-a treatment was
able to increase the levels of ceramide, in this case, by
35%. The bulk of the increase mainly concerned a sub-
set of ceramide molecular species: C16:0, C24:1, and
C18:0 ceramides (Table 1). TNF-a action also resulted
in a 30% decrease in sphingomyelin, especially the C16:0
and C24:1 molecular species, reflecting an activation of
sphingomyelinases (Table 1). To assess whether cera-
mide accumulation could explain the atrophic effects of
TNF-a, we investigated the effects of myotube treatment
by exogenous ceramide. Interestingly, in both the L6
and C2C12 cell lines, the atrophic effects of TNF-a
were mimicked by the addition to the culture medium
of cell-permeating short-chain ceramides, particularly
C6 ceramide (Figure 1a-c; see Additional file 1), suggest-
ing that myotube atrophy might result from TNF-a-
induced ceramide accumulation.
Inhibitors of ceramide synthesis prevent TNF-a-induced
myotube atrophy
To confirm the role of ceramide formation in the
atrophic response to TNF-a, inhibitors of ceramide
synthesis were added to the culture medium simulta-
neously with TNF-a. Ceramide can be formed by two
different pathways (under the action of sphingomyeli-
nases or through de novo synthesis), and TNF-a is
known to activate both pathways [2,3]. Thus, two types
of agents were used: myriocin, an inhibitor targeting de
novo synthesis by selectively inhibiting the first step of
the pathway catalyzed by serine-palmitoyl-CoA transfer-
ase [21], and GW4869 [22] and 3-O-methylsphingomye-
lin (OMS) [23], two inhibitors of sphingomyelinases.
Myriocin was able to protect L6 myotubes from the
TNF-a-induced decrease in surface. GW4869 and OMS
were also able to counteract the TNF-a atrophic effect
in L6 myotubes, suggesting that ceramide formed by
either of the pathways mediates the atrophic effect of
TNF-a (Figure 2a). The inhibitors had little influence
on myotube surface in the absence of TNF-a,a l t h o u g h
there was a weak positive effect for GW4869 and OMS.
No additive effects of the inhibitors of the two different
ceramide-synthesis pathways were seen (Figure 2a).
The effects of ceramide-synthesis inhibition in L6
myotubes were also evaluated using other markers of
muscle-cell integrity. Myriocin significantly decreased
the TNF-a-induced loss of MHC content as evaluated
by ELISA (Figure 2b), and prevented the loss of myosin
light chains 1 and 3, as evaluated by western blotting
(Figure 2c). Moreover, all of the studied inhibitors of
ceramide synthesis had a protective effect against TNF-
a-induced CK activity alteration. Again, their actions
were not additive (Figure 2d).
In C2C12 myotubes, GW4869 and OMS also showed
protective effects against TNF-a-induced atrophy,
whereas myriocin was devoid of protective effects, and
in fact, produced by itself a negative effect on myotube
size, contrary to its effects on L6 myotubes (see Addi-
tional file 2). This suggests that, in C2C12 cells, cera-
mide formed by sphingomyelinase activation is
predominant in the induction of atrophy by TNF-a
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Figure 1 Effects of tumor necrosis factor (TNF)-a and exogenous ceramide on L6 myotube characteristics. (A) Differentiated myotubes
treated for 3 days with 15 ng/ml TNF-a or 5 μmol/l C6 ceramide were immunostained for sarcomeric myosin heavy chain (MHC), and their
surfaces were evaluated by using Image J software. The graph shows the myotube area (mean ± SE) expressed as a percentage of the field
surface, as determined in ten fields, and is representative of at least three experiments. Different from control: **P = 0.01; ***P = 0.001. (B) The
MHC content of myotubes treated for 3 consecutive days with TNF-a or C6 ceramide at the indicated concentrations was evaluated by ELISA.
The mean ± SE of three measurements expressed as a percentage of control values is shown. The mean control value was 75 ± 11 μg of MHC
per 120,000 cells. *Different from control: P < 0.05; P ≤ 0.001. (C) The creatine kinase activity of myotubes treated for 3 days with 15 ng/ml TNF-
a or 5 μmol/l C6 ceramide was assayed in triplicate (mean ± SE).*Different from control: P < 0.05.
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for these cells to maintain their homeostasis, by supply-
ing cells with an essential component.
The effects of ceramide-synthesis inhibitors on the
changes in cellular levels of sphingolipids induced by
TNF-a were assessed in L6 myotubes. Both the de novo
synthesis inhibitor myriocin and the sphingomyelinase
inhibitors GW4869 and OMS significantly inhibited the
TNF-a-induced increase in ceramide levels (Figure 3a),
confirming that the drugs were active at the concentra-
tions used, and suggesting that ceramide accumulation
results from the activation of both pathways under the
action of TNF-a. As expected, treatment with GW4869
and OMS alleviated the TNF-a-induced loss of sphingo-
myelin (Figure 3b). By contrast, myriocin by itself
decreased sphingomyelin levels and amplified the sphin-
gomyelin-lowering effect of TNF-a,i na g r e e m e n tw i t h
its reported ability to induce a general depletion of
sphingolipids, including sphingomyelin [19].
Are changes in S1P levels also involved in myotube size
regulation?
Because ceramide can be rapidly metabolized in the cell,
and potentially converted into the bioactive mediator S1P
through the sequential action of ceramidases and sphin-
gosine kinases [5], we evaluated the effects of S1P on
myotubes. In L6 myotubes, exogenous S1P in the pre-
sence of TNF-a had a positive effect, on myotube surface
and on CK activity (Figure 4a, b), suggesting that cera-
mide metabolization into S1P can induce effects opposite
to that of ceramide itself. This antagonistic action was
also supported by the observation that S1P also decreased
the atrophic effects of ceramide (Figure 4c). Conversely,
inhibition of S1P biosynthesis by the addition of the
sphingosine kinase inhibitors D-L-threo-dihydro-sphin-
gosine (DHS) and N,N-dimethylsphingosine (DMS) [24]
increased the effects of TNF-a and ceramide on myotube
surface or CK activity, supporting the assumption that
S1P at least partly antagonizes the effects of ceramide
(Figure 4b, c). S1P can be secreted and is known to acti-
vate a set of specific membrane surface receptors, of
which S1P1, S1P2, and S1P3 are expressed in muscle
cells [25]. The effects of FTY720, a compound function-
ally acting as an inhibitor of S1P receptors [26], were
thus evaluated. FTY720 itself had negative effects on
myotubes, consistent with a positive influence of S1P, but
FTY720 did not amplify the negative effects of TNF-a
(Figure 4a, b).
Protein metabolism is altered by ceramide production
Protein synthesis rate was evaluated in L6 myotubes by
measuring the incorporation of [
3H]-tyrosine into neo-
synthesized proteins. The marked decrease in protein
synthesis induced by a 12-hour TNF-a treatment was
significantly counteracted by the addition of either myr-
iocin or OMS (Figure 5a). Proteolysis was also quanti-
fied in [
3H]-tyrosine labeled L6 myotubes, by measuring
the release of trichloroacetic acid-soluble radioactivity.
In the presence of TNF-a for 12 hours, both myriocin
and OMS were able to decrease proteolysis significantly
(Figure 5b). These results strongly suggest that ceramide
formation negatively influences protein synthesis,
whereas it activates proteolysis.
Part of cell proteolysis involves the ubiquitin-protea-
some system, and ubiquitin ligases are important com-
p o n e n t so ft h i ss y s t e m .I nmuscle, atrophy is often
associated with upregulation of a set of genes called
atrogenes, including the genes encoding the ubiquitin
ligases Atrogin-1 and Murf1, which target muscle-speci-
fic proteins [27]. We thus evaluated the effect of cera-
mide-synthesis inhibitors on ubiquitin ligase mRNA
expression, and found that TNF-a increased expression
Table 1 Effect of tumor necrosis factor (TNF)-a treatment on ceramide and sphingomyelin content of L6 myotubes.
1
Principal
molecular
species
Ceramide Sphingomyelin
Control, pmol/
μg protein
TNF-a, pmol/
μg protein
TNF-a-induced increase,
% of total control
2
Control, pmol/
μg protein
TNF-a, pmol/
μg protein
TNF-a-induced decrease,
% of total control
2
C16:0 4.87 ± 0.82 6.21 ± 1.06 11.5 ± 5.1 69.7 ± 10.54 47.2 ± 7.66 20.4 ± 2.1
C18:0 1.76 ± 1.11 2.48 ± 0.74 6.2 ± 2.8 6.28 ± 0.94 5.35 ± 0.82 1.1 ± 0.1
C20:0 0.07 ± 0.07 0.38 ± 0.09 1.8 ± 0.3 1.29 ± 0.13 1.12 ± 0.11 0.16 ± 0.07
C22:1 0.51 ± 0.15 0.72 ± 0.14 1.5 ± 0.6 3.17 ± 0.32 2.77 ± 0.38 0.54 ± 0.07
C22:0 0.65 ± 0.18 1.05 ± 0.19 2.3 ± 0.8 3.15 ± 0.6 2.62 ± 0.46 0.55 ± 0.14
C24:1 4.77 ± 0.91 6.32 ± 1.16 9.2 ± 2.3 13.7 ± 2.44 10.00 ± 1.81 2.72 ± 0.22
C24:0 1.35 ± 0.33 1.44 ± 0.21 1.5 ± 0.7 5.01 ± 1.03 4.39 ± 0.94 0.55 ± 0.08
Total 14.70 ± 3.40 19.70 ± 3.85 35.5 ± 8.8 118.8 ± 17.2 85.7 ± 13.1 30.4 ± 2.1
1Data are the mean ± SE of five measurements.
2TNF-a-induced change in one particular molecular species, expressed as a percentage of the sum of all molecular species in the control.
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Figure 2 The negative effects of tumor necrosis factor (TNF)-a on L6 myotubes are counteracted by ceramide-synthesis inhibition. (A)
Myotube area was measured after 3 days in the presence or absence of 15 ng/ml TNF-a, with the addition of 100 nmol/l myriocin, 10 μmol/l
GW4869, or 1 μmol/l 3-0-methylsphingomyelin (OMS), or with myriocin plus either GW4869 or OMS. Shown are the mean ± SE of 5 to 9
experiments, with 10 fields considered for each condition. ***Different from all the other conditions: P ≤ 0.001. (B) ELISA quantification of the
MHC content of myotubes treated for 3 days with 15 ng/ml TNF-a, with or without 100 nmol/l myriocin. The means ± SE of three
measurements expressed as a percentage of control values are shown. ***Different from the other conditions: P ≤ 0.005. (C) Western blot
analysis of myosin light chains (MLC) 1 and 3 from myotubes treated for 3 days with 15 ng/ml TNF-a, with or without 100 nmol/l myriocin. The
diagram shows the quantification of MLC1 and MLC3 levels, after normalization by tubulin levels. Shown are the mean ± SE of three
determinations. **Different from control and from TNF-a: P ≤ 0.002; *different from control: P ≤ 0.05. (D) Creatine kinase activity of myotubes
treated or not by TNF-a, in the presence of 100 nmol/l myriocin, or 10 μmol/l GW4869, or 1 μmol/l OMS, or both myriocin and GW4869 or
OMS. Shown are the mean ± SE of three determinations made in triplicate. ***Different from all the other conditions: P ≤ 0.001.
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Page 5 of 19of Atrogin-1, whereas myriocin, GW4869 and OMS
markedly decreased its expression, confirming that cera-
mide formation is able to enhance proteolysis (Figure
5c). By contrast, no significant effect of ceramide inhibi-
tion on Murf1 expression was seen (not shown).
Because a well-identified target of Atrogin-1 in muscle
tissue is the translation initiation factor subunit eIF3f
(eukaryotic translation initiation factor 3, subunit f), the
degradation of which plays a major role in atrophy [28],
we assessed the amount of the eIF3f protein, and found
that it was significantly reduced in TNF-a-treated myo-
tubes. Addition of myriocin resulted in a partial rever-
sion of this reduction (see Additional file 3), suggesting
that TNF-a-induced, ceramide-dependent, Atrogin-1
upregulation has a negative effect on protein synthesis
and myotube size through the degradation of eIF3f, and
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Figure 3 Inhibitors of ceramide synthesis modulate tumor necrosis factor (TNF)-a effects on myotube sphingolipid content. (A) Total
ceramide levels were determined in myotubes treated for 3 days with TNF-a, without or with 100 nmol/l myriocin, 10 μmol/l GW4869, or 1
μmol/l OMS. Results are expressed as a percentage of control value, and are the mean ± SE of 3 to 5 determinations. ++Different from control: P
= 0.02; *different from TNF-a alone: P = 0.05, **:P = 0.02, ***P < 0.001. Mean ± SE control value is 14.7 ± 3.4 pmol ceramide/μg proteins. (B)
Total sphingomyelin levels were determined in myotubes treated for 3 days with TNF-a, without or with 100 nmol/l myriocin, 10 μmol/l
GW4869, or 1 μmol/l OMS. Results are expressed as a percentage of control value, and are the mean ± SE of 3 to 5 determinations. ++Different
from control: P = 0.002, +++P < 0.001; *different from TNF-a alone: P = 0.05, **P = 0.02. Mean ± SE control value is 118.8 ± 17.2 pmol
sphingomyelin/μg proteins.
De Larichaudy et al. Skeletal Muscle 2012, 2:2
http://www.skeletalmusclejournal.com/content/2/1/2
Page 6 of 19conversely, that the preservation of eIF3f might partici-
pate in the protective effects of ceramide-synthesis inhi-
bition on muscle cells.
Another proteolytic system that is known to contri-
bute to muscle atrophy is autophagy [29], a typical mar-
ker of which is LC3b, a protein constituent of
autophagosomes [30]. We found that ceramide-synthesis
inhibitors significantly decreased the expression of LC3b
in the presence of TNF-a, suggesting that ceramide also
participates in enhancing proteolysis in myotubes
through the autophagic system (Figure 5c). However,
ceramide-synthesis inhibitors did not induce significant
downregulation of other autophagy marker genes such
as Beclin-1, Gabarapl1 or CathepsinL (not shown). It
has been reported that both proteasomal and autophagic
protein degradation pathways are under the control of
the Foxo3 transcription factor, which regulates the
expression of atrogenes, including Atrogin-1, and of
autophagy-related genes such as LC3b [29]. Foxo tran-
scription factors are negatively regulated by Akt-
mediated phosphorylation, which induces their exclusion
from the nucleus and thereby inhibits their transcrip-
tional activity [16]. We evaluated the phosphorylation
status of Foxo3 in myotubes and, consistent with the
induced changes in atrogene expression, TNF-a-treat-
ment caused a significant dephosphorylation, that is, an
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inhibition. (A) Myotubes were treated for 12 hours with TNF-a, in the presence or absence of 100 nmol/l myriocin, or 1 μmol/l OMS. The rate
of protein synthesis was measured by adding [
3H]-tyrosine to the culture medium, and counting the radioactivity present in trichloroacetic acid
(TCA) precipitates of the cells, in relation to the total protein content. The results are the mean ± SE of three determinations. ++Different from
control: P = 0.001; *different from TNF-a alone: P≤ 0.05. (B) Proteolysis was measured in L6 myotubes labeled with [
3H]-tyrosine for 48 h, and
treated for 12 hours with TNF-a in the presence or absence of 100 nmol/l myriocin, 1 μmol/l OMS, or both. TCA-soluble radioactivity released in
the medium was measured and related to the total incorporated radioactivity. The results are the mean ± SE of three determinations. *Different
from TNF-a alone: P < 0.05. (C) The mRNA levels of Atrogin-1 and LC3b were measured by reverse transcription quantitative PCR in myotubes
treated or not with TNF-a in the presence of 100 nmol/l myriocin, 10 μmol/l GW4869, or 1 μmol/l OMS, and normalized to the TATA box
binding protein mRNA. Results are the mean ± SE of 3 to 5 measurements in duplicate. **Different from control without drug: P = 0.01; ++
+different from TNF-a alone: P≤ 0.001, +P < 0.05. (D) Myotubes were treated for 3 days with or without TNF-a, in the presence of 100 nmol/l
myriocin. Phospho- Ser253 Foxo3 in cell extracts was analyzed by western blotting. Results were normalized by total Foxo3 protein amounts.
*Different from all other values: P < 0.02.
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Page 8 of 19activation of this factor. This effect was suppressed by
myriocin addition, confirming a role of ceramide in
TNF-a-induced proteolysis enhancement (Figure 5d).
Molecular mechanism of ceramide effects on muscle cells
Ceramide is known to be a downregulator of the expres-
sion of PLD, particularly the PLD1 isoform [9,31]. PLD
is in turn an activator of mTOR kinase, a major regula-
tor of protein synthesis and degradation [15], closely
involved in muscle-tissue homeostasis [32]. We there-
fore assessed the influence of TNF-a and ceramide-
synthesis inhibitors on the expression of PLD1 in L6
myotubes. Myriocin by itself had no influence on PLD1
mRNA, whereas GW4868 alone moderately increased
the PLD1 mRNA level. TNF-a strongly repressed the
expression of PLD1 mRNA, and ceramide-synthesis
inhibitors rescued its expression, with myriocin resulting
in partial, and GW4869 in total rescue. In fact, potentia-
tion of the effects of the two inhibitors on PLD1 mRNA
levels was seen (Figure 6a). These effects were con-
firmed at the protein level, with TNF-a inducing a
marked decrease in PLD1 protein, which was rescued by
either myriocin or GW4869 (Figure 6a). These results
thus indicated that TNF-a lowers PLD1 expression in
myotubes through the production of ceramide both by
the de novo pathway and by sphingomyelinase
activation.
It could be expected that the observed changes in
PLD1 expression induced by TNF-a, and their reversion
by ceramide-synthesis inhibitors, directly influenced the
activity of mTOR kinase, an important regulator of pro-
tein metabolism. Indeed, we recently found that phos-
pholipase D is able to activate both protein complexes
involving mTOR kinase (mTORC1 and mTORC2) in L6
myoblasts [17]. A well-identified effector of mTORC1
that positively regulates protein translation is S6 kinase
(S6K)1 [15]. We evaluated by western blotting the phos-
p h o r y l a t i o no fS 6 K 1o nt h eT h r 3 8 9r e s i d u e ,w h i c h
reflects its activation state. Contrary to what we
expected, we found that S6K1 phosphorylation was
barely affected by TNF-a alone; however, it was mark-
edly increased by myriocin addition in the presence of
TNF-a (+80%). Under the same conditions, total S6K1
protein was also increased, by 40% (Figure 6b, right
panel). This increase was paralleled by a 36% increase in
S6K1 mRNA, as evaluated by reverse transcription
quantitative PCR (Figure 6b, left panel). It can thus be
inferred that, in the presence of TNF-a, ceramide-synth-
esis inhibition affects protein synthesis by increasing
both the expression and the phosphorylation of the
mTORC1 effector S6K1.
A k tk i n a s ei sam T O R C 2s u b s t r a t et h a tp l a y sam a j o r
role in the control of proteolysis [16]. We thus evaluated
the phosphorylation of Akt on Ser473 residues, a
reflection of its activation state. Here again, there was
an unexpected finding, namely that TNF-a alone tended
to have a positive (although not significant) effect, rather
than a negative one, on Akt phosphorylation. This posi-
tive effect was markedly amplified in the presence of
either myriocin or GW4869, with Akt activation being
significant whether phospho-Akt was normalized by the
amount of tubulin in the samples, or by the amount of
total Akt protein (Figure 6c). Thus, in the presence of
TNF-a, activation of the mTORC2 substrate Akt is
likely to participate in the decrease in proteolysis
induced by ceramide-synthesis inhibition.
Together, these data indicated that in L6 myotubes,
PLD1 upregulation induced by ceramide-synthesis inhi-
bition in the presence of TNF-a is related to the upre-
gulation and activation of the well-known anabolic
factors S6K1 and Akt.
Because TNF-a is well known as an activator of the
NFB pathway [2] that can activate protein catabolism
[33], we further investigated the effect of ceramide-
synthesis inhibition by myriocin on the phosphorylation
of NFB inhibitor kinase subunit-a/b (IKK-a/b), an
essential step of the NFB activation cascade [33]. We
found that TNF-a treatment of L6 myotubes was able
to rapidly induce IKKa/b phosphorylation, reaching a
maximum in 30 minutes. Notably, myriocin treatment
had no influence on this response, suggesting that
sphingolipid metabolism was not involved in the activa-
tion of NFB pathway in our setting (see Additional file
4).
In vivo inhibition of ceramide synthesis protects mice
against tumor-induced muscle atrophy
The development of C26 tumors in the mice is known
to induce severe cachexia, characterized by a rapid loss
of muscle mass [14]. Cancer-induced muscle wasting is
thought to be related to strongly increased circulating
levels of pro-inflammatory cytokines, particularly TNF-a
[34]. To evaluate the protective potentialities of cera-
mide-synthesis inhibition against muscle wasting, we
treated C26-bearing mice with myriocin, a drug that has
the ability to decrease muscle ceramide levels in vivo
[8]. The development of the C26 tumor induced a rapid
fall in the animals’ weight after 10-15 days, confirming
the occurrence of cachexia. Tumor-induced muscle
atrophy was assessed by measuring the weights of the
gastrocnemius and tibialis anterior muscles, and the
cross-sectional area (CSA) of myofibers in these mus-
cles. Under the effect of tumor growth, the gastrocne-
mius and tibialis weights were decreased by 22% and
26%, respectively (Figure 7a), and the mean CSA in
these muscles was reduced by 45% and 31%, respectively
(Figure 7b). Myriocin treatment had no effect on the
timing of cachexia onset or on tumor size (not shown),
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mRNA levels were measured by reverse transcription quantitative PCR, and normalized to the TATA box binding protein mRNA. Results are the
mean ± SE of 3 to 6 measurements in duplicate. *Different from TNF-a alone: P = 0.05, **P < 0.001; different from control: P≤ 0.05. (Right panel)
PLD1 protein in cell extracts was analyzed by western blotting. Results were normalized to the amount of tubulin, and are the mean ± SE of
three experiments. **Different from control: P < 0.01; +different from TNF-a alone: P = 0.02. (B) Myotubes were treated for 3 days with or
without TNF-a, in the presence of 100 nmol/l myriocin. (Left panel) S6K1 mRNA levels were measured by reverse transcription quantitative PCR
and normalized to the TATA box binding protein mRNA. Results are the mean ± SE of three measurements in duplicate. **Different from both
control and TNF-a alone: P < 0.01. (Right panel) Total S6K1 protein and phospho-Thr389 S6K1 in cell extracts were analyzed by western blotting.
Results were normalized to the amount of tubulin, and are the mean ± SE of three determinations. +Different from control: P < 0.05; ++P < 0.02;
**different from both control and TNF-a alone: P < 0.02. (C) Myotubes were treated for 3 days with or without TNF-a, in the presence of 100
nmol/l myriocin or 10 μmol/l GW4869. Ph-Ser473 Akt was analyzed by western blotting. Results were normalized to the amount of (left panel)
tubulin or (right panel) total Akt, and are the mean ± SE of 3 to 5 determinations. NS, not significantly different from control. ***Different from
TNF-a: P < 0.001, **P < 0.01, *P < 0.05.
De Larichaudy et al. Skeletal Muscle 2012, 2:2
http://www.skeletalmusclejournal.com/content/2/1/2
Page 10 of 19A
tibialis
NS  
*      
0
500
1000
1500
2000
2500
3000
control myr tumor tumor+myr
C
S
A
,
 
μ
m
2 NS
+
+  + *
gastrocnemius
0
200
400
600
800
1000
1200
1400
1600
1800
2000
control myr tumor tumor+myr
C
S
A
,
 
μ
m
2
++
+
+ +
***
B
C
gastrocnemius
myofiber CSA (μm2)
p
e
r
c
e
n
t
 
o
f
 
m
y
o
f
i
b
e
r
s
0
0
400
800
1200
1600
2000
2400
2800
3200
3600
4000
5
10
15
20
25
30
tumor
tumor+myr
control
myr
¶
¶
¶
¶
¶
¶
*
*
+
+
¶
0
20
40
60
80
100
120
140
gastrocnemius
m
u
s
c
l
e
 
w
e
i
g
h
t
,
 
m
g
control
myr
tumor
tumor+myr
tibialis
*
+
+ +
+
+ +
E
0
10 0
200
300
400
500
600
700
control  myr tumor tumor+myr
c
e
r
a
m
i
d
e
,
 
p
m
o
l
e
s
/
m
g
 
w
e
t
 
w
e
i
g
h
t
p =0.002 p=0.08
D
Foxo3
0
0,05
0,1
0,1 5
0,2
0,25
0,3
0,35
0,4
control myr tumor tumor+myr
m
R
N
A
 
r
e
l
a
t
i
v
e
 
l
e
v
e
l
s
Atrogin-1
0
5
10
15
20
25
30
35
control myr tumor tumor+myr
m
R
N
A
 
r
e
l
a
t
i
v
e
 
l
e
v
e
l
s
MurF1
0
50
10 0
150
200
250
300
350
control myr tumor tumor+myr
m
R
N
A
 
r
e
l
a
t
i
v
e
 
l
e
v
e
l
s
Foxo1
0
0,05
0,1
0,1 5
0,2
0,25
0,3
0,35
0,4
control myr tumor tumor+myr
m
R
N
A
 
r
e
l
a
t
i
v
e
 
l
e
v
e
l
s
*
**
¶
¶
***
***
Figure 7 Myriocin protects muscle tissue from tumor-induced atrophy. (A) Mice were inoculated or not with C26 adenocarcinoma, and
were injected daily or not with 0.1 mg/kg myriocin. The gastrocnemius and tibialis muscles were dissected and weighed (mean ± SE of 5 to 7
experiments for gastrocnemius; 7 to 10 for tibialis). +++Different from control: P < 0.0001; *different from ‘tumor’: P = 0.05. (B) Mean cross-
sectional area (CSA) of myofibers was evaluated on transverse sections of gastrocnemius and tibialis muscles (mean ± SE of four experiments for
gastrocnemius, seven for tibialis). +++Different from control: P < 0.0001, ++P < 0.01; ***different from ‘tumor’: P = 0.0002, *P = 0.05. (C)
Frequency distribution of myofiber CSA in gastrocnemius (mean ± SE of four experiments). ‘Tumor’ different from ‘tumor+myriocin’, P < 0.002,
+P < 0.01, *P < 0.05. (D) mRNA expression of atrophy-related genes in gastrocnemius was evaluated by reverse transcription quantitative PCR,
and normalized to cyclophilin A mRNA. Results are the mean ± SE of four determinations in duplicate. *Different from control, P < 0.05; **P <
0.01; ***P < 0.001; different from ‘tumor’, P < 0.05. (E) Total ceramide levels were measured in the tibialis of the differently treated mice (mean ±
SE, four experiments).
De Larichaudy et al. Skeletal Muscle 2012, 2:2
http://www.skeletalmusclejournal.com/content/2/1/2
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skeletal muscles in the presence of tumor, with a signifi-
cant increase of +11% in the tibialis muscle (Figure 7a).
In control mice, myriocin treatment alone had a small
negative effect on mean CSA in both muscles ((-16% in
gastrocnemius (significant) -10% in tibialis (non-signifi-
cant)), but in the presence of tumor, myriocin treatment
significantly counteracted the CSA decrease (Figure 7b).
Taking into account the size distribution of myofibers in
gastrocnemius, the presence of tumor was clearly asso-
ciated with the disappearance of the largest fiber popu-
lation, and myriocin restored the presence of large fibers
at the expense of the small-fiber population (Figure 7c).
The atrophic effect of the tumor was also illustrated
by a large increase in the expression of the Atrogin-1
and MurF1 atrogenes, and a significant increase in the
expression of the Foxo1 and Foxo3 transcription factors,
which are positive regulators of atrogene expression
[16]. Treatment of tumor-bearing mice with myriocin
significantly decreased expression of Atrogin-1 and
Foxo3 (Figure 7d).
To evaluate whether ceramide levels were altered in
muscle tissue under the different conditions, ceramide
was quantified in the tibialis muscles of the same mice.
In agreement with our assumption that ceramide is
involved in atrophy, the tumor induced a marked
increase in muscle ceramide level (+53%). Myriocin
treatment of tumor-bearing mice lowered ceramide
levels, although the difference did not reach statistical
significance (Figure 7e). By contrast, no significant varia-
tions in sphingomyelin levels were detected (not shown).
Together, these observations show that blocking de
novo ceramide synthesis has an anti-atrophic effect in
vivo in tumor-bearing mice.
Discussion
In this study, we found that in vitro TNF-a treatment
was able to significantly decrease the surface area of
myotubes deriving from either the L6 or the C2C12
lines, with this effect being reproduced by addition of
cell-permeating ceramides.F u r t h e r m o r e ,b o t hT N F - a
and ceramide decreased the CK activity and MHC con-
tent of L6 myotubes. These observations suggested that
the atrophic effects of TNF-a on muscle cells might rely
on the production of ceramide triggered by the cytokine.
To verify this hypothesis, we used different ceramide-
synthesis inhibitors together with TNF-a.B o t hade
novo pathway inhibitor (myriocin) and two sphingomye-
linase inhibitors (GW4869 and OMS) were able to sup-
press the effects of TNF-a on L6 myotube size, myosin
heavy and light chain content, and CK activity, suggest-
ing that ceramide formed by either of the pathways
mediates the atrophic effects of TNF-a. The effects of
inhibitors of the two different ceramide-synthesis
pathways were not additive, suggesting that a mere
reduction in ceramide formation, rather than complete
suppression, is enough to prevent cell atrophy. Alterna-
tively, this could result from the overall depletion of
sphingolipids induced by the blockade of de novo synth-
esis by myriocin [19], which potentially also reduced
sphingomyelinase-mediated ceramide synthesis. The
sphingomyelinase inhibitors GW4869 and OMS also
showed protective effects against TNF-a-induced atro-
phy in C2C12 myotubes, thereby confirming the invol-
vement of ceramide formed by sphingomyelinase
activation. However, in this cell line, myriocin was
devoid of protective effects and in fact, showed a nega-
tive effect by itself on myotube size, contrary to the
results in L6 myotubes. A possible explanation is that in
the C2C12 line de novo sphingolipid synthesis has to be
maintained above a certain threshold, so as to supply
cells with a compound that can be either a structural
component such as sphingomyelin or a glycosylcera-
mide, or a mediator such as S1P, and this would be
essential to maintain cell homeostasis.
Quantification of the sphingolipids established that
TNF-a markedly increased the ceramide content of L6
myotubes, consistent with a role for this sphingolipid
mediator in the atrophic response. Ceramide accumula-
tion was accompanied by a substantial decrease in
sphingomyelin cell content, showing that ceramide
resulted, at least in part, from sphingomyelin hydrolysis.
However, among the molecular species of ceramide
formed under TNF-a stimulation, the C18:0 species was
found to be one of the most important (its increase
representing 6.2% of the sum of ceramide species in the
control), whereas there was no parallel hydrolysis of
C18:0-sphingomyelin (Table 1). It can thus be hypothe-
s i z e dt h a tT N F - a was able to induce de novo synthesis
of C18:0 ceramide, and to produce other species, mainly
C16:0 and C24:1 ceramides, via sphingomyelinase activa-
tion. Myriocin totally prevented the TNF-a-induced rise
in ceramide, and in parallel decreased the levels of
sphingomyelin, supporting the above proposal that it is
able to inhibit both the de novo and the sphingomyeli-
nase pathways of ceramide synthesis. Similar to myrio-
cin, the sphingomyelinase inhibitors were able to
diminish TNF-a-induced ceramide rise, although to a
lesser extent, and as expected, these inhibitors signifi-
cantly restored the sphingomyelin cellular content. On
the whole, these data are compatible with the interpreta-
tion that myotube atrophy induced by TNF-a involves
accumulation of ceramide, and that the inhibitors coun-
teracted the TNF-a effects by preventing ceramide
synthesis.
Because ceramide can be rapidly metabolized and give
rise to other mediators, of which S1P has particular
importance in cell physiology [5], we considered the
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in the response of L6 myotubes to TNF-a stimulation.
We found that S1P displayed a positive influence on
myotube integrity, opposite to that of exogenous cera-
mide or TNF-a. A lowering of S1P availability might
thus participate in the negative effects of TNF-a.C o n -
sistent with this idea, these effects were not amplified by
S1P receptor inhibition, suggesting that S1P levels had
already been reduced below an effective concentration
by TNF-a treatment. These observations are in agree-
ment with the reported attenuation of denervation-
induced soleus atrophy by S1P perfusion in the rat [35].
It is well known that muscle atrophy results from both
decreased protein synthesis and accelerated proteolysis.
In agreement with a pro-atrophic role of TNF-a,w e
found that the cytokine lowered protein synthesis and
tended to increase proteolysis in L6 myotubes. These
effects were reversed by the ceramide-synthesis inhibi-
tors myriocin and OMS, indicating that ceramide is
involved in the effects of TNF-a on protein metabolism.
Concerning the elements of the proteolytic machinery
that are regulated by ceramide, we could observe that
ceramide-synthesis inhibition markedly lowered the
expression of Atrogin-1 ubiquitin ligase, which was
increased by TNF-a. As this atrogene plays a recognized
role in the catabolism of muscle-specific proteins, at
least part of the TNF-a/ceramide atrophic effects can be
related to the modulation of this factor, and to the
resulting decrease in eIF3f translation initiation factor
levels. In addition, we found that ceramide-synthesis
inhibitors significantly lowered the expression of LC3b,
an essential component of the autophagic proteolytic
system. The activation of autophagy by ceramide has
already been described in other cell systems [13]. It is
thus possible that ceramide positively regulates both
proteasome- and autophagy-dependent protein degrada-
tion in differentiated myotubes, possibly through coordi-
nated changes in Foxo3 transcription factor
phosphorylation. However, the transcriptional regulation
of autophagy by ceramide in L6 myotubes remains spec-
ulative, in view of the absence of effect of ceramide-
synthesis inhibitors on the expression of several other
autophagy-related genes.
Protein homeostasis is, for a large part, under the con-
trol of signaling pathways of which the central elements
are the kinases Akt and mTOR. These interconnected
regulators integrate inputs from growth factors, nutrient
availability, and energy levels so as to adapt protein
synthesis and degradation to the physiological status of
the cell. Akt is a major inhibitor of proteolysis through
the control of Foxo transcription factors, which in turn
regulate the expression of ubiquitin ligases involved in
the specific degradation of muscle proteins by protea-
some [16]. mTOR kinase, in complex with the protein
Raptor (mTORC1 complex), is indirectly activated by
Akt, through phosphorylation of its inhibitor tuberous
sclerosis complex [15]. Activated mTORC1 is known to
enhance protein translation, particularly through the
activation of its substrate S6K1, and has been shown to
be required for muscle hypertrophy [36]. mTORC1 is
also a major negative regulator of autophagy [15].
Furthermore, mTOR also exists in complex with the
protein Rictor to form the mTORC2 complex, which is
able to phosphorylate and activate Akt. Both mTOR
complexes are stimulated by the phospholipid messen-
ger phosphatidic acid [17,18], the product of the action
of the signaling enzyme of cell membranes, PLD. More-
over, involvement of PLD in mTOR activation in
response to exercise has been shown, suggesting its role
in muscle-tissue hypertrophy [37].
Ceramide is considered a general inhibitor of PLD, act-
ing at the catalytic site, on the recruitment of activator
proteins, and also at the transcriptional level [38]. We
previously found that ceramide selectively inhibits
e x p r e s s i o no ft h eP L D 1i s o f o r mo ft h ee n z y m ei nL 6
myoblasts [9]. In the present study, we found that TNF-a
markedly decreased expression of PLD1, and that cera-
mide-synthesis inhibitors rescued its expression, suggest-
ing that PLD1 is one major target of ceramide in this
signaling network. Because PLD is an activator of both
mTOR complexes, we then considered the influence of
these inhibitors on the mTORC1 substrate S6K1 and the
mTORC2 substrate Akt. Ceramide inhibition in the pre-
sence of TNF-a increased the amounts of both S6K1 and
Akt under the phosphorylated/activated state, possibly as
a consequence of PLD1 upregulation. However, a discre-
pancy between PLD1 expression and S6K1/Akt phos-
phorylation state was apparent under the effect of TNF-a
alone, which downregulated PLD1 without affecting, or
even slightly enhancing, either S6K1 or Akt phosphoryla-
tion. A possible explanation for this is that the pleiotropic
cytokine TNF-a may trigger other signaling pathways
that are able to positively influence Akt and mTORC1,
and thereby mask any negative effects of ceramide on
S6K1 and Akt. By suppressing these negative effects, cer-
amide-synthesis inhibition would allow further activation
of these mTOR effectors. Inhibition of TNF-a-induced
ceramide accumulation could thus have positive trophic
effects on muscle cells, at least partly through the upre-
gulation of PLD1 and the resulting activation of S6K1
and Akt, which respectively enhance protein synthesis
and reduce proteolysis. However, TNF-a by itself altered
protein synthesis without having significant effects on
S6K1 and Akt, thus we hypothesize that the cytokine
triggered other undefined mTOR-independent pathways
that negatively influenced proteosynthesis.
Another mechanism by which ceramide-synthesis
inhibition might result in Akt stimulation and positive
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ity of ceramide to hamper insulin/insulin-like growth
factor (IGF) signaling in muscle tissue [6,39]. Myriocin
has thus been shown to decrease muscle ceramide levels
and insulin resistance in mice placed on a high-fat diet
[7,8]. Because IGFs are involved in trophic effects on
muscle tissue [40], it is possible that in our study myrio-
cin acted on myocyte size, both in vitro and in vivo,
through the enhancement of signaling by endogenously
produced IGF, and downstream Akt activation. How-
ever, we found no changes in IRS-1 tyrosine phosphory-
lation under TNF-a and myriocin treatments of L6
myotubes (not shown), which makes a role for IGF sig-
naling in the effects of myriocin very unlikely. In addi-
tion, our in vitro results suggest that myriocin does not
modulate proteolysis by targeting the NFBp a t h w a y ,
and thus that this pathway is not regulated by ceramide
in muscle cells.
Finally, our study addressed the in vivo role of cera-
mide in a model of tumor-induced cachexia. The devel-
opment of C26 adenocarcinoma induced a marked
increase in ceramide levels in mouse muscle, together
with severe atrophy. A low dose of myriocin (0.1 mg/kg)
significantly limited muscle loss, reduced expression of
some atrogenes, and partially restored myocyte size,
confirming that ceramide accumulation participates in
enhanced proteolysis and muscle atrophy. As for the
small negative effect of myriocin alone on myocyte size,
it might be attributable, similarly to the hypothesis for
C2C12 cells, to a lowered supply in sphingolipid(s)
involved in the maintenance of muscle-tissue
homeostasis.
Conclusions
This study has established that inhibition of ceramide
synthesis has beneficial effects on myocyte size under
conditions inducing muscle atrophy. The sphingolipid
pathway thus could be a possible target of interventions
aiming at protecting muscle tissue against the wasting
that occurs in various pathological situations, particu-
larly during cancer-induced cachexia. The therapeutic
potential of inhibitors of de novo ceramide synthesis and
of sphingomyelinase action thus deserves further investi-
gation. In addition, because ceramide synthesis depends
on cell availability in palmitic acid, and can be altered
by the composition of fatty acid dietary intake [41,42], it
will be of interest to consider nutritional interventions
targeting the sphingolipid pathway in the treatment of
muscle atrophy.
Methods
GW4869 was from Sigma-Aldrich (L’Isle-d’abeau,
France). Sphingosine-1-phosphate, DHS, and 3-OMS
were obtained from Enzo Life Sciences (Paris, France).
C6 ceramide and N,N-dimethylsphingosine were from
Biomol Research Laboratories Inc., (Plymouth Meeting,
PA, USA). FTY 720 was from Cayman Chemical Com-
pany (Ann Arbor, MI, USA). Anti-phospho-Thr389/
Thr412-S6K1 antibody, anti-S6K1 antibody, anti-phos-
pho-Ser473-Akt antibody, anti-Akt antibody, anti-phos-
pho-Ser176/180-IKKa/b and anti-PLD1 polyclonal
antibody were from Cell Signaling Technology (Beverly,
MA, USA). Anti-eIF3f antibody was from Rockland (Gil-
bertsville, PA, USA). Anti-Foxo3 and anti-phospho-
Ser253-Foxo3 antibodies were from Millipore (Billerica,
MA, USA). Anti-a-Tubulin monoclonal antibody was
supplied by Sigma. Anti-myosin light chain 1 and 3
monoclonal F310 antibody and anti-sarcomeric MHC
MF-20 antibody were from the Developmental Studies
Hybridoma Bank, University of Iowa (Iowa City, USA).
HRP-conjugated anti-rabbit-IgG antibodies were from
Jackson Immunoresearch Laboratories (Soham, UK).
Cell culture
L6 myoblasts of the C5 subclone were maintained in
Dulbecco’s modified Eagle’sm e d i u m( D M E M )w i t h4 . 5
g/l glucose, supplemented with 10% (v/v) fetal bovine
s e r u ma t3 7 ° Ca n d5 %C O 2. To induce differentiation,
cells were seeded at a density of 5.10
5 cells per well in
six-well plates, and cultured in DMEM supplemented
with 1% fetal bovine serum and 10
-7 mol/l arginine-
vasopressin (AVP; Sigma-Aldrich) for 5 days. The myo-
tubes obtained were then treated with 15 ng/mL recom-
binant rat TNF-a (Immunotools, Friesoythe, Germany).
for 3 days to induce atrophy, in the presence or absence
of sphingolipid synthesis inhibitors. The effect of TNF-a
on cell viability was determined by 3-(4,5-dimethyl-2
thiazoyl)-2,5-diphenyl-2H-tetrazolium bromide (MTT)
assay (Roche Diagnostics, Meylan, France) in 96-well
plates. At the end of TNF-a treatment of differentiated
myotubes, they were supplemented with 0.5 mg/mL
MTT for 4 h at 37°C. After this incubation period, pur-
ple formazan salt crystals formed, and were dissolved in
solubilization solution overnight. Optical density was
measured at 550 and 690 nm, using an ELISA plate
reader (PowerWave X, Biotek Instruments, Winooski,
VT, USA). The number of viable cells directly correlated
with the difference between the 550 and 690 nm absor-
bance results.
Electrophoresis and western blotting
Cells were lyzed in ice-cold buffer containing 20 mmol/l
Tris-HCl, 100 mM NaCl, 10 mmol/l sodium pyropho-
sphate, 10 mmol/l glycerophosphate, 50 mmol/l sodium
fluoride, 1.5 mmol/l Na3VO4, 1% Triton, and a protease
inhibitor cocktail (pH 7.6). Lysates were kept on ice dur-
ing 15 minutes and separated by centrifugation at
13,000 g for 15 minutes. Bradford protein assay (Bio-
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aliquot of the solution. Cell lysates were analyzed by
SDS-PAGE, and proteins were transferred onto PVDF
membranes blocked with 5% BSA in Tris-buffered sal-
ine/0.1% Tween 20, and incubated with the various anti-
bodies (see Materials) following the manufacturers’
recommendations. Immunoblots were visualized with
the ECL detection system (Pierce Biotechnology Inc.,
Rockford, Illinois, USA) and quantified with Image J
software http://rsb.info.nih.gov/ij/. SDS-PAGE was per-
formed using 10% polyacrylamide gels for S6K1, Akt
and IKKa/b, and 12% polyacrylamide gels for myosin
light chains. In the case of PLD1, the protein was immu-
noprecipitated before electrophoresis. The cell lysate was
incubated with capture anti-PLD1 polyclonal antibody
(Cell Signaling Technology) overnight at 4°C with con-
tinuous mixing. Protein G magnetic beads (PurePro-
teome Protein G Magnetic Beads Kit; Millipore,
Billerica, MA, USA) were pre-washed with PBS (phos-
phate-buffered saline) containing 0.1% Tween 20, and
50 μL of these were added to the preformed antibody-
antigen complex, then the suspension was incubated for
30 min at 4°C. The beads were collected with a magnet,
washed in PBS/0.1% Tween, and the elution was per-
formed with Laëmmli buffer 1:3 in lysis buffer. The elu-
ate was heated at 70-90°C for precisely 2 min (to
prevent PLD1 aggregation known to occur in overheat-
ing conditions). Samples were subjected to SDS-PAGE
on 8% acrylamide gels, in the presence of 4 mol/l urea,
then transferred to PVDF membrane, and western blot-
ting was performed with anti-PLD1 monoclonal anti-
body (H00005337-M02; Abnova, Taipei, Taiwan))
diluted 1:500 in TBS/0.1% Tween 20.
Measurement of sphingolipid levels
Sphingolipids were extracted by the Bligh and Dyer
method [43]. Muscle tissue was homogenized (Precellys
24 Homogenizer; Bertin Technologies, Montigny-le-Bre-
tonneux, France) in chloroform:methanol (1:2 v/v) using
1 ml of solvent per 10 mg of wet tissue, in a. Myotubes
were scraped into 500 μl0 . 1NH C li nP B S ,a n d2m L
chloroform/methanol (1:2 v/v) were added. An aliquot
of the mixture was kept for Bradford protein assay.
Internal deuterium-labeled standards were added at this
step: C16:0 D31 ceramide (N-palmitoyl(d31)-D-erythro-
sphingosine), and C16:0 D31 sphingomyelin (N-palmi-
toyl(d31)-D-erythro-sphingosylphosphorylcholine)
(Avanti Polar Lipids Inc., Alabaster, AL, USA). The sam-
ples were mixed by vortex for 30 seconds, sonicated,
and let to stand for 30 minutes at room temperature.
One volume of water and one volume of chloroform
were added to perform phase separation. The samples
were then vortexed again for 1 minute before centrifu-
gation at 750 g for 5 minutes. The lower organic phase
was transferred to a clean collection tube, and evapo-
rated under a nitrogen stream at 37°C. The dry extracts
were kept at -20°C until analysis by electrospray tandem
mass spectrometry (ESI MS/MS), carried out on a tri-
ple-quadrupole mass spectrometer (API 3200 MS/MS;
Sciex Applied Biosystems, Toronto, Canada) equipped
with an ion spray source (TurboIonSpray; Applied Bio-
s y s t e m s ,F o s t e rC i t y ,C A ,U S A )h e a t e dt o5 0 0 ° C .T w o
binary pumps, a vacuum degasser and a high-perfor-
mance autosampler (Agilent 1200 Series; Agilent Tech-
nologies, Massy, France) with a control module (Instant
Pilot; Agilent Technologies) were used for solvent deliv-
ery and automated sample introduction. All results were
acquired with Analyst software (version 1.5; AB Sciex
LLC, Foster City, CA, USA). For measurement of sphin-
gomyelin, the MS/MS was performed in negative ioniza-
tion mode. Specific parameters used were as follows: ion
spray voltage - 4500 V; entrance potential -9.5 V;
declustering potential -120 V; collision energy -100 eV.
For the measurement of ceramide, the MS/MS was per-
formed in positive ionization mode. Specific parameters
used were as follows (in arbitrary units) ion spray vol-
tage 5500 V; entrance potential -10 V; declustering
potential 100 V; collision energy 40 eV. Sample analysis
for quantification was performed in multiple reaction
monitoring (MRM) mode by flow injection analysis (for
specific MRM values corresponding to each ceramide or
sphingomyelin species and to the corresponding internal
standard, see Additional file 5). The dwell time was
fixed to 30 ms for each species. Sphingomyelin and cer-
amide were measured separately, with two different
acquisition methods and two different injections (20 μl
and 5 μl, respectively), with a flow rate of 200 μl/min
2:1 chloroform:methanol (analysis time of 3 minutes).
The concentration of each molecular species was calcu-
lated from the ratio of its signal to that of the corre-
sponding internal standard. Total ceramide and
sphingomyelin concentrations were the sum of the con-
centrations of the various species.
Measurement of the area of immunofluorescence-labeled
myotubes
The differentiated myotubes were fixed with 3.7% for-
maldehyde for 20 minutes at room temperature and
permeabilized with 0.1% Triton for 10 minutes at room
temperature, then aspecific labeling was blocked with
1% BSA for 20 minutes. Anti-myosin MF-20 antibody
was added diluted 1:50 and incubated for 1 hour at
room temperature. After washing with PBS/1% BSA,
rhodamine-conjugated anti-mouse IgG antibody was
added diluted 1:500 in 1% BSA for 1 hour at room tem-
perature. Nuclei were stained with 1 μg/mL 4.5-diami-
dino-2-phenylindole (DAPI) for 3 minutes. The cells
were examined by immunofluorescence microscopy
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20x/0.30 PHI ∞/40, an Axiocam MRM camera and
Axiovision 4.1 image-acquisition software; Carl Zeiss,
Göttingen, Germany). Differentiated myotubes, but not
myoblasts, were evenly labeled on their entire surface.
Their area was measured by the method of Sultan et al.
[44], using Image J software.
Assay of creatine kinase activity
Cells were seeded at a density of 5.10
5 cells per well in
six- well plates and scraped into 500 μlo fi c e - c o l dl y s i s
buffer. The assay was performed using a commercial kit
(CK-NAC LD B Kit; Sobioda, Montbonnot-St Martin,
France) which allows monitoring at 340 nm of the
kinetics of formation of NADPH, produced by an enzy-
matic cascade initiated by CK. The assay was performed
in 96-well plates, with 4 μL of sample per well, for 20
minutes at 30°C.
ELISA of myosin heavy chain
The cells were grown in 12-well plates at a density of
3.10
4 cells per cm
2. After completion of differentiation
and 3 days of treatment with TNF-a and various sphin-
golipid synthesis inhibitors, the cells were scraped into
300 μL ice-cold RIPA buffer, mixed by vortex and sepa-
rated by centrifugation at 10,000 g for 10 minutes. The
assay was carried out in 96-well plates. Samples (50 μL)
were evaporated to dryness overnight at 37°C, then the
wells were washed twice with cold PBS. All washing
steps were performed using an automatic plate washer
(ELx50 Autostrip Washer from Bio-Tek Instruments,
Inc.). Aspecific binding sites were saturated with 100 μL
of 0.1% BSA in PBS for 30 minutes at 37°C. Samples
were then incubated with 50 μL MF-20 antibody, diluted
1:100 in PBS, for 1 hour at 37°C. After another washing
step, samples were incubated with 50 μL of secondary
HRP-conjugated anti-mouse antibody (Jackson Immu-
noresearch Laboratories, Soham, UK) diluted 1:3000, for
1 hour at 37°C. Plates were washed five times, then 50
μL of TMB substrate (Sigma-Aldrich) were added to
each well, and 0.5 N H2SO4 was added after 5 minutes
to stop the color reaction. Optical density was read at
450 nm. A standard curve was obtained with purified
MHC (Sigma-Aldrich).
Measurement of protein synthesis
Protein synthesis rates were assayed according to Gulve
and Dice [45], with some modifications. Myotubes were
treated for 12 hours with TNF-a and various inhibitors.
Culture medium was then replaced by experimental
medium containing 2 μCi/mL of [
3H]-L-Tyrosine (Per-
kin-Elmer, Waltham, MA, USA) and non-radioactive
tyrosine up to 2 mol/l and incubated for 1 hour. Culture
monolayer was washed five times with ice-cold PBS.
Cells were scraped into 10% trichloroacetic acid (TCA)
on ice, mixed by vortex and separated by centrifugation
at 12,000 g for 10 minutes to separate the pellet con-
taining labeled neosynthesized proteins from the super-
natant containing the pool of non-incorporated [
3H]-L-
Tyrosine. The pellet was then dissolved in cell lysis buf-
fer and neutralized with 1 mol/l NaOH. An aliquot was
taken for Bradford protein analysis. Determination of
radioactivity was performed in a liquid-scintillation
spectrometer (Hewlett-Packard, Palo Alto, CA, USA).
Measurement of protein degradation
Rates of protein degradation were determined by moni-
toring the release of TCA-soluble radioactivity in the
culture medium at defined time, after radiolabeling pro-
teins with [
3H]-L-tyrosine. Long-lived proteins were
radiolabeled by incubating the cells with 2 μCi/mL of
[
3H]-L-Tyrosine under differentiating conditions for 2
days, until completion of differentiation. Cells were
rinsed three times with PBS and shifted for 2 hours in
chase medium (DMEM 1% fetal bovine serum and non-
radioactive tyrosine to prevent reincorporation of [
3H]-
L-Tyrosine) to allow degradation of short-lived proteins.
Cells were washed again, and the medium replaced.
After 12 hours, samples (0.5 mL) of the culture medium
were taken and supplemented with 10% (w/v) TCA.
After standing at 4°C for 1 h, samples were separated by
centrifugation at 12,000 g f o r1 0m i n u t e s ,t os e p a r a t e
the pellet of precipitated proteins from the free amino
acids resulting from protein degradation. The pellet was
dissolved with 0.5 mL lysis buffer and neutralized with 1
mol/l NaOH. The monolayer was washed three times
with PBS and scraped into lysis buffer to determine cell-
associated radioactivity. Proteolysis was evaluated as the
percentage of TCA-soluble radioactivity released in the
medium relative to the total incorporated radioactivity.
Reverse transcription and real-time PCR
T o t a lR N Aw a si s o l a t e df r o mL 6m y o t u b e su s i n gT r i z o l
reagent (Invitrogen Corp., Carlsbad, CA, USA). Total
RNA (1 μg) was used for reverse transcription, in the
presence of 100 U reverse transcriptase (Superscript II;
Invitrogen Corp.), random hexamers and oligo dT. Real-
time PCR was performed with a commercial kit (Fast
Start DNA Master Sybr Green Kit (Roche Diagnostics)
using a thermal cycler (Rotor-Gene 6000; Corbett
Research, Mortlake, Australia). Data were analyzed with
LightCycler software (Roche Diagnostics) and normal-
ized either to TATA box binding protein (TBP), or to
cyclophilin A housekeeping gene transcripts. Specific
sense and anti-sense primers used for amplification are
shown in Table 2.
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Animals were treated in strict accordance with the
guidelines of the Institutional Animal Care and Use
Committee and to relevant national and European legis-
lation, throughout the experiments.
Male BALB/c mice, 6 weeks old, were used (Charles
River Laboratories Italia, Milan, Italy). Animals were
housed in the animal facility under conventional condi-
tions with constant temperature and humidity, and fed a
standard diet. Tumor implantation was performed using
cubic pieces of approximately 1 mm
3 of solid C26
tumor kept in liquid nitrogen. Tumor pieces were
injected, using a trocar needle, under the dorsal skin of
mice anesthetized with sodium pentobarbital 30 mg/kg.
C o n t r o lm i c ew e r ei n j e c t e dw i t hs a l i n eo n l y .T h ea n i -
mals were weighed every day. From day 8, a palpable
tumor was visible.
Half of the control mice and half of mice with tumors
were injected intraperitoneally with 0.1 mg/kg of a 2
mg/ml myriocin (Sigma-Aldrich) solution in 0.5%
methanol. Control mice received 0.5% methanol in sal-
ine. Myriocin was injected un t i lt h ee n do ft h ee x p e r i -
ment. When the tumor-injected mice had lost 3 g of
weight, they were killed by cervical dislocation. At the
same time, a matched control (no tumor injection, same
dose of myriocin) was also killed. The tumor-injected
mice and matched controls were killed between days 13
and 17. The tibialis and gastrocnemius muscles were
dissected from both hind limbs, weighed, and frozen in
liquid N2-cooled isopentane and stored at -80°C for
either histological or molecular analyses. Muscle
sections (10 μm) were cut on a cryostat microtome, and
stained with hematoxylin and eosin. Fiber CSAs (500
fibers per muscle) were measured using NIH ImageJ
software.
Statistical analyses
The statistical significance of data was assessed by
ANOVA and Fisher tests, using StatView software ver-
sion 5.0 (SAS Institute Inc., Cary, NC, USA).
Additional material
Additional file 1: Both tumor necrosis factor (TNF)-a and ceramide
induce atrophy of C2C12 myotubes. C2C12 myoblasts were
differentiated in 2% horse serum-containing medium. The obtained
myotubes were then treated with the various agents for 3 days, and
then fixed and stained with periodic acid-Schiff technique [21]. The
surface of randomly chosen 100 individual myotubes was measured
using Scion Image Beta software (version 4.02; Scion Corporation,
Frederick, MD, USA). (A) C2C12 myotubes were treated with various
concentrations of mouse recombinant TNF-a, or 0.3 μg/ml
cycloheximide used as a positive control. ***Different from control: P <
0.001. Representative of four experiments. (B) C2C12 myotubes were
treated with various concentrations of cell-permeant C2, C6, or C8
ceramide. ***Different from control: P < 0.001. Representative of four
experiments.
Additional file 2: GW4869 and 3-O-methylsphingomyelin, but not
myriocin, prevent tumor necrosis factor (TNF)-a-induced atrophy of
C2C12 myotubes. C2C12 myotubes obtained as above were treated for
3 days with 1 ng/ml TNF-a, in the presence of various ceramide-
synthesis inhibitors. They were fixed and immunolabelled for sarcomeric
myosin heavy chain, and their surface was measured in 10 fields in each
condition, using the method of Sultan et al. [21], with Image J software.
(A) Effect of 100 nmol/l myriocin. ***Different from control: P < 0.001.
Representative of four experiments. (B) Effect of 10 μmol/l GW4869, or 1
μmol/l 3-O-methylsphingomyelin (3-OMS). ***Different from control: P <
0.001; ++different from TNF-a alone: P < 0.01. Representative of four
experiments.
Additional file 3: Tumor necrosis factor (TNF)-a and myriocin affect
the amount of the Atrogin-1 target eIF3f (eukaryotic translation
initiation factor 3 subunit f). L6 myotubes were treated for 3 days with
or without TNF-a, in the presence of 100 nmol/l myriocin. The eIF3f
protein level in cell extracts was analyzed by western blotting. Results
were normalized to the amount of tubulin, and are the mean ± SE of
four measurements. +++Different from control: P < 0.0001; *different
from TNF- alone: P < 0.05,**P < 0.01.
Additional file 4: Lack of effect of ceramide-synthesis inhibition on
the nuclear factor (NF)B pathway. L6 myotubes were treated for 10
minutes, or for the indicated time, with tumor necrosis factor (TNF)-a in
the absence or presence of 100 nmol/l myriocin. Phospho-IKK-a/b (NFB
inhibitor kinase subunit-a/b) was analyzed by western blotting. The
experiment shown is representative of two performed.
Additional file 5: Parameters of tandem mass spectrometry
sphingolipid analyses. (A) Physiological ceramide species: m/z mass of
the [M+H- H2O]
+ ion for measurement in multiple reaction monitoring
(MRM) mode. Product ion was m/z 264.3. C16:0-D31 ceramide was used
as internal standard. (B) Physiological sphingomyelin species: m/z mass
of the [M-H]
- ion for measurement in MRM mode. Product ion was m/z
79. C16:0-D31 sphingomyelin was used as internal standard.
List of abbreviations
AVP: arginine-vasopressin; BSA: bovine serum albumin; CSA: cross-sectional
area; DMEM: Dulbecco’s modified Eagle’s medium; IGF: insulin-like growth
Table 2 Primers used for reverse transcription
quantitative PCR.
Name Direction Sequence 5’®3’
PLD1 Sense GGTCAGAAAGATAACCCAGG
Anti-sense GAAGCGAGACAGCGAAATGG
Atrogin-1 Sense CTCTGCCAGTACCACTTCTC
Anti-sense ATGGTCAGTGCCCCTCCAGG
LC3b Sense CTGGACAAGACCAAGTTCCT
Anti-sense AAGCCGTCTTCATCTCTCTC
S6K1 Sense AGAGCACCTGCGTATGAATC
Anti-sense CACTGACTCTTTGAGACTGCC
Murf1 Sense TGCATCTCCATGCTGGTGGC
Anti-sense CTTCTTCTCGTCCAGGATGG
Foxo1a Sense AGATCTACGAGTGGATGGTG
Anti-sense GGACAGATTGTGGCGAATTG
Foxo3a Sense GAGAGCAGATTTGGCAAAGG
Anti-sense CCTCATCTCCACACAGAACG
TBP Sense TGGTGTGCACAGGAGCCAAG
Anti-sense TTCACATCACAGCTCCCCAC
Cyclophilin A Sense ATGGCACTGGTGGCAAGTCC
Anti-sense TTGCCATTCCTGGACCCAAA
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Page 17 of 19factor; MHC: myosin heavy chain; mTOR: mammalian target of rapamycin;
OMS: 3-O-methylsphingomyelin; PLD: phospholipase D; PVDF: polyvinylidene
fluoride; S1P: sphingosine-1-phosphate; TNF-α: tumor necrosis factor alpha.
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